Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
Clinical trial NCT04507919 · NO_LONGER_AVAILABLE
Trial details
- NCT number
- NCT04507919
- Sponsor
- Novartis Pharmaceuticals
- Status
- NO_LONGER_AVAILABLE
- Study type
- EXPANDED_ACCESS
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.